# E137: Obexelimab in IgG4-RD (INDIGO)

Page: https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e137-obexelimab-in-igg4-rd-indigo
Text version: https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e137-obexelimab-in-igg4-rd-indigo.md
Podcast: [The Evidence Based Rheumatology Podcast](https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175)
Published: 2026-06-29T19:14:56+00:00
Episode link: https://msputman.podbean.com/e/e137-obexelimab-in-igg4-rd-indigo/
Audio file: https://mcdn.podbean.com/mf/web/93p3tikzrv3tcmvs/e137.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/the-evidence-based-rheumatology-podcast-1130175/episodes/e137-obexelimab-in-igg4-rd-indigo
Duration seconds: 936

## Resource

Another day, another B cell drug. This one adds an interesting option for IgG4-RD, offering a "maybe less efficacious maybe less toxic" pathway. I could see folks being excited for this, especially in a disease where non-scary-manifestations are relatively common. Also, check out boardsbank.com! Paper: https://www.nejm.org/doi/full/10.1056/NEJMoa2601337

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/the-evidence-based-rheumatology-podcast-1130175/episodes/e137-obexelimab-in-igg4-rd-indigo/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e137-obexelimab-in-igg4-rd-indigo.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.